Electroceuticals World Market Study, 2019: Coverage of Epilepsy, Cardiovascular Diseases, Rheumatoid Arthritis & Diabetes Treatment Using Electroceuticals

News provided by

Nov 21, 2019, 14:45 ET

DUBLIN, Nov. 21, 2019 /PRNewswire/ -- The "Electroceuticals: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The report includes:

An overview of global markets and technologies for electroceuticals
Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
Discussion on why electroceuticals are considered as an alternative to drug-based remedies
Identification of endogenous and exogenous factors that are impacting the global market growth
Coverage of several diseases such as epilepsy, cardiovascular diseases, rheumatoid arthritis and diabetes and their treatment using electroceuticals
Information on RecoveryRx medical device, which is used for the treatment of postoperative pain of opioid/NSAID therapy
Comprehensive profiles of leading companies in the industry, including Abbott Laboratories Inc., Biotronik Inc., Cochlear Corp., GlaxoSmithKline Plc and Sonova AG

This report provides a comprehensive summary of electroceutical technologies and global markets, along with detailed profiles of key market players, a revenue product portfolio and recent activities. This report analyzes trends and dynamics, including drivers, limitations, challenges and opportunities. This report discusses strategies adopted by emerging market players, with recommendations for new market entrants.

This research study discusses historical, current and potential market size. This report will help market players and new entrants make informed decisions about the production and export of goods and services. Organizations, distributors and exporters should find the information about market development and trends useful. This study segments the market on the basis of applications and end use. Geographic market analysis is provided for all major segments.

Market Highlights

The global electroceuticals market is expected to grow significantly due to various factors: rising incidence and prevalence of chronic diseases, growing investment into the development of advanced electroceuticals and government backing. For instance, GSK PLC and Microsoft Corp. invested significantly into the R&D of advanced electroceutical devices. In 2016, the companies collaborated to form Galvani Bioelectronics, planning to invest $715 million over the next seven years into R&D programs. Around 55% of the stake is owned by GSK PLC, 45% by Microsoft Corp.

A growing geriatric population is another major factor that is expected to surge market growth during the forecast period. The elderly population is at an increased risk of developing various diseases: Parkinson's, Alzheimer's, cardiac arrhythmias and epilepsy. Per the World Bank, around 9.0% of the global population is geriatric with an increased risk of neurological disease. According to the Alzheimer's Association, in 2019, around 5.8 million Americans of all ages are living with Alzheimer's dementia. Out of this 5.8 million, 5.6 million were age 65+.

Significant investment in the electroceuticals industry is another major factor creating considerable opportunity in the global electroceuticals market. Medtronic PLC, Boston Scientific, Biotronik, Cochlear Ltd., Demant A/S and GlaxoSmithKline PLC have been spending significantly on R&D programs related to the advance electroceutical devices. In 2016, NIH announced a fund of $248 million that was distributed to public and private research communities through Stimulating Peripheral Activity to Relieve Conditions (SPARC) to develop future electroceuticals. Such a huge amount of funding activity in the electroceuticals industry will boost the growth of the market in the near future.

Increasing prevalence of medical conditions such as neurological disorders (epilepsy, Parkinson's, paraneoplastic neurologic syndrome, migraines and much more) results in increased R&D for the development of electroceuticals. Per the Institute for Health Metrics and Evaluation, around 10 million people were living with Parkinson's disease in 2019, globally. Every year more than a million new cases of Parkinson's disease are registered, globally. There are more than 1.3 billion people living with hearing loss, across the globe, which is expected to drive the hearing aid and cochlear implant market.

Key Topics Covered

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Market Definition
North America
Cardioverter Defibrillators and Cardiac Pacemaker Segment
R&D
Public Access Defibrillators (PAD)
Asia Pacific
Battery Technology
Factors Driving Market Growth
CVD
Product Launch
Growing Geriatric Population
Factors Restraining Market Growth
Alternative Drugs: Treatment of Arrhythmia
Stringent Government Regulations
Hackable Pacemakers
Low Awareness
Opportunities
Growing Healthcare Expenditures

Chapter 4 Market Breakdown by Technology Type

Cardioverter Defibrillators and Cardiac Pacemakers
Deep Brain Stimulators (DBS)
Spinal Cord Stimulators (SCS)
Vagus Nerve Stimulators
Hearing Aids and Cochlear Implants
Others (Sacral Nerve Stimulators, Transcutaneous Electrical Nerve Stimulators)

Chapter 5 Market Breakdown by End User

Hospitals and Clinics
Homecare and Others

Chapter 6 Market Breakdown by Region

North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Rest of Asia Pacific
Rest of The World
Latin America
The Middle East and Africa

Chapter 7 Patent Review/New Developments

Chapter 8 Analysis of Market Opportunities

Key Manufacturers
Key Players
Abbott Laboratories Inc.
Boston Scientific Corp.
Demant A/S
Medtronic PLC
Sonova Holding AG
Premarket Approval (PMA) Of Electroceuticals

Chapter 9 Company Profiles

Abbott Laboratories Inc.
Advanced Bionics Ag
Aleva Neurotherapeutics Sa
Axonics Modulation Technologies Inc.
Bioelectronics Corp.
Biotronik Inc.
Boston Scientific Corp.
Cala Health Inc.
Cochlear Corp.
Demant A/S
Edwards Lifesciences Corp.
Electrocore Inc.
Functional Neuromodulation Ltd.
Glaxosmithkline Plc
Getinge Ab
Gn Store Nord
Hangzhou Nurotron Biotechnology Co. Ltd.
Lepu Medical Technology (Beijing) Co. Ltd.
Livanova Plc
Medtronic Plc
Neuropace, Inc.
Nevro Corp.
Nuvectra Corp.
Second Sight Medical Products Inc.
Sivantos Pte. Ltd.
Sonova Ag
Starkey Hearing Technologies
Stimwave Llc
Terumo Corp.
Zoll Medical Corp.

For more information about this report visit https://www.researchandmarkets.com/r/8y8nwh

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets